HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A

Sang Y. Lee, Siying Liu, Ryan M. Mitchell, Becky Slagle-Webb, Young Soo Hong, Jonas M. Sheehan, James R. Connor

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

HFE is a protein that impacts cellular iron uptake. HFE gene variants are identified as risk factors or modifiers for multiple diseases. Using HFE stably transfected human neuroblastoma cells, we found that cells carrying the C282Y HFE variant do not differentiate when exposed to retinoic acid. Therefore, we hypothesized HFE variants would impact response to therapeutic agents. Both the human neuroblastoma and glioma cells that express the C282Y HFE variant are resistant to Temodar, geldanamycin and γ-radiation. A gene array analysis revealed that p16INK4A (p16) expression was increased in association with C282Y expression. Decreasing p16 protein by siRNA resulted in increased vulnerability to all of the therapeutic agents suggesting that p16 is responsible for the resistance. Decreasing HFE expression by siRNA resulted in a 85% decrease in p16 expression in the neuroblastoma cells but not the astrocytoma cells. These data suggest a potential direct relationship between HFE and p16 that may be cell specific or mediated by different pathways in the different cell types. In conclusion, the C282Y HFE variant impacts the vulnerability of cancer cells to current treatment strategies apparently by increasing expression of p16. Although best known as a tumor suppressor, there are multiple reports that p16 is elevated in some forms of cancer. Given the frequency of the HFE gene variants, as high as 10% of the Caucasian population, these data provide compelling evidence that the C282Y HFE variant should be part of a pharmacogenetic strategy for evaluating treatment efficacy in cancer cells.

Original languageEnglish (US)
Pages (from-to)2104-2114
Number of pages11
JournalInternational Journal of Cancer
Volume129
Issue number9
DOIs
StatePublished - Nov 1 2011

Fingerprint

Neuroblastoma
temozolomide
Small Interfering RNA
Neoplasms
Cyclin-Dependent Kinase Inhibitor p16
Pharmacogenetics
Astrocytoma
Tretinoin
Gene Frequency
Glioma
Genes
Iron
Radiation
Therapeutics
Population
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lee, Sang Y. ; Liu, Siying ; Mitchell, Ryan M. ; Slagle-Webb, Becky ; Hong, Young Soo ; Sheehan, Jonas M. ; Connor, James R. / HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A. In: International Journal of Cancer. 2011 ; Vol. 129, No. 9. pp. 2104-2114.
@article{a7343062044d4078a4e01776e005a54a,
title = "HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A",
abstract = "HFE is a protein that impacts cellular iron uptake. HFE gene variants are identified as risk factors or modifiers for multiple diseases. Using HFE stably transfected human neuroblastoma cells, we found that cells carrying the C282Y HFE variant do not differentiate when exposed to retinoic acid. Therefore, we hypothesized HFE variants would impact response to therapeutic agents. Both the human neuroblastoma and glioma cells that express the C282Y HFE variant are resistant to Temodar, geldanamycin and γ-radiation. A gene array analysis revealed that p16INK4A (p16) expression was increased in association with C282Y expression. Decreasing p16 protein by siRNA resulted in increased vulnerability to all of the therapeutic agents suggesting that p16 is responsible for the resistance. Decreasing HFE expression by siRNA resulted in a 85{\%} decrease in p16 expression in the neuroblastoma cells but not the astrocytoma cells. These data suggest a potential direct relationship between HFE and p16 that may be cell specific or mediated by different pathways in the different cell types. In conclusion, the C282Y HFE variant impacts the vulnerability of cancer cells to current treatment strategies apparently by increasing expression of p16. Although best known as a tumor suppressor, there are multiple reports that p16 is elevated in some forms of cancer. Given the frequency of the HFE gene variants, as high as 10{\%} of the Caucasian population, these data provide compelling evidence that the C282Y HFE variant should be part of a pharmacogenetic strategy for evaluating treatment efficacy in cancer cells.",
author = "Lee, {Sang Y.} and Siying Liu and Mitchell, {Ryan M.} and Becky Slagle-Webb and Hong, {Young Soo} and Sheehan, {Jonas M.} and Connor, {James R.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1002/ijc.25888",
language = "English (US)",
volume = "129",
pages = "2104--2114",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A. / Lee, Sang Y.; Liu, Siying; Mitchell, Ryan M.; Slagle-Webb, Becky; Hong, Young Soo; Sheehan, Jonas M.; Connor, James R.

In: International Journal of Cancer, Vol. 129, No. 9, 01.11.2011, p. 2104-2114.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A

AU - Lee, Sang Y.

AU - Liu, Siying

AU - Mitchell, Ryan M.

AU - Slagle-Webb, Becky

AU - Hong, Young Soo

AU - Sheehan, Jonas M.

AU - Connor, James R.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - HFE is a protein that impacts cellular iron uptake. HFE gene variants are identified as risk factors or modifiers for multiple diseases. Using HFE stably transfected human neuroblastoma cells, we found that cells carrying the C282Y HFE variant do not differentiate when exposed to retinoic acid. Therefore, we hypothesized HFE variants would impact response to therapeutic agents. Both the human neuroblastoma and glioma cells that express the C282Y HFE variant are resistant to Temodar, geldanamycin and γ-radiation. A gene array analysis revealed that p16INK4A (p16) expression was increased in association with C282Y expression. Decreasing p16 protein by siRNA resulted in increased vulnerability to all of the therapeutic agents suggesting that p16 is responsible for the resistance. Decreasing HFE expression by siRNA resulted in a 85% decrease in p16 expression in the neuroblastoma cells but not the astrocytoma cells. These data suggest a potential direct relationship between HFE and p16 that may be cell specific or mediated by different pathways in the different cell types. In conclusion, the C282Y HFE variant impacts the vulnerability of cancer cells to current treatment strategies apparently by increasing expression of p16. Although best known as a tumor suppressor, there are multiple reports that p16 is elevated in some forms of cancer. Given the frequency of the HFE gene variants, as high as 10% of the Caucasian population, these data provide compelling evidence that the C282Y HFE variant should be part of a pharmacogenetic strategy for evaluating treatment efficacy in cancer cells.

AB - HFE is a protein that impacts cellular iron uptake. HFE gene variants are identified as risk factors or modifiers for multiple diseases. Using HFE stably transfected human neuroblastoma cells, we found that cells carrying the C282Y HFE variant do not differentiate when exposed to retinoic acid. Therefore, we hypothesized HFE variants would impact response to therapeutic agents. Both the human neuroblastoma and glioma cells that express the C282Y HFE variant are resistant to Temodar, geldanamycin and γ-radiation. A gene array analysis revealed that p16INK4A (p16) expression was increased in association with C282Y expression. Decreasing p16 protein by siRNA resulted in increased vulnerability to all of the therapeutic agents suggesting that p16 is responsible for the resistance. Decreasing HFE expression by siRNA resulted in a 85% decrease in p16 expression in the neuroblastoma cells but not the astrocytoma cells. These data suggest a potential direct relationship between HFE and p16 that may be cell specific or mediated by different pathways in the different cell types. In conclusion, the C282Y HFE variant impacts the vulnerability of cancer cells to current treatment strategies apparently by increasing expression of p16. Although best known as a tumor suppressor, there are multiple reports that p16 is elevated in some forms of cancer. Given the frequency of the HFE gene variants, as high as 10% of the Caucasian population, these data provide compelling evidence that the C282Y HFE variant should be part of a pharmacogenetic strategy for evaluating treatment efficacy in cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=80052264607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052264607&partnerID=8YFLogxK

U2 - 10.1002/ijc.25888

DO - 10.1002/ijc.25888

M3 - Article

C2 - 21190189

AN - SCOPUS:80052264607

VL - 129

SP - 2104

EP - 2114

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -